A recent randomized, placebo-controlled clinical trial has demonstrated that semaglutide, marketed as Ozempic and Wegovy, can slow and potentially reverse biological aging in humans. The 32-week study involved 108 HIV patients with lipohypertrophy who were randomized to receive either semaglutide or a placebo. Results showed that participants treated with semaglutide exhibited a reduction in epigenetic age by an average of 3.1 years, with some organs appearing nearly five years younger based on multiple epigenetic aging clocks. This trial represents the first high-quality evidence supporting the anti-aging effects of semaglutide beyond its established use for weight loss. While the findings highlight semaglutide’s potential as a longevity medication, some concerns have been raised about its impact on muscle size and strength. Concurrent research is also exploring the role of diet and gut microbiome in healthy aging, suggesting a multifactorial approach to age-related health maintenance.